An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Novartis0 sites521 target enrollmentFebruary 2002

ConditionsVascular Dementia

DrugsRivastigmine

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Vascular Dementia
Sponsor: Novartis
Enrollment: 521
Primary Endpoint: Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Registry

clinicaltrials.gov

Start Date

February 2002

End Date

May 2006

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Novartis

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate.